移至標頭移至導覽移至內部移至註腳

研究成果 (4)

排序依據：日期 | 題名

10 | 25 | 50 | 100

上一頁

上一頁

1/1

下一頁

最後一頁

4 A B C D E F G H I L M N O P Q R S T U V W Z 全部

Bevacizumab in the treatment of non-small cell lung cancer: focus on East Asia
Mok TSK ( 2011 )
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
Publication in policy or professional journal
數位物件識別號 (DOI): http://dx.doi.org/10.1111/j.1743-7563.2011.01401.x
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang HY, Armour AA, To KF, Yang JCH, Mok TSK ( 2011 )
JOURNAL OF CLINICAL ONCOLOGY
Publication in refereed journal
數位物件識別號 (DOI): http://dx.doi.org/10.1200/JCO.2010.33.4235
Biomarker Analysis in BO21015, a Phase II Randomized Study of First-line Bevacizumab (BEV) Combined with Carboplatin-gemcitabine (CG) or Carboplatin-paclitaxel (CP) in Patients (pts) With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC)
MOK Shu Kam Tony, GORBUNOVA V, JUHASZ E, SZIMA B, BURDAEVA O, YU Cj, DELMAR P, PALLAUD C, JONNAERT M, RECK M ( 2011 )
The European Journal of Cancer 16th ECCO
Invited conference paper presented and published in conference proceedings
Breast cancer in Hong Kong, Southern China: the first population-based analysis of epidemiological characteristics, stage-specific, cancer-specific, and disease-free survival in breast cancer patients: 1997-2001
KWONG A, MANG O W, WONG C H, CHAU W W, LAW S C, YEO Winnie ( 2011 )
Annals of Surgical Oncology
Publication in refereed journal

10 | 25 | 50 | 100

上一頁

上一頁

1/1

下一頁

最後一頁